Trump officials plan coverage for weight loss drugs under Medicare and Medicaid

The Trump administration plans a five-year pilot program allowing Medicaid and Medicare to voluntarily cover GLP-1 weight loss drugs, such as Ozempic and Wegovy, for general weight management, marking a significant federal policy shift. This initiative, slated for April 2026 (Medicaid) and January 2027 (Medicare), could incur substantial public costs given the drugs' high annual price of $5,000-$7,000. However, it represents a massive market expansion for manufacturers like Eli Lilly and Novo Nordisk, with analysts projecting the weight-loss drug market could exceed $150 billion by the next decade, evidenced by Eli Lilly's premarket share increase.

Analysis

The Trump administration's plan to launch a five-year pilot program for Medicare and Medicaid coverage of GLP-1 drugs represents a significant potential expansion of the total addressable market for manufacturers like Eli Lilly and Novo Nordisk. This policy shift, targeting coverage for "weight management," could unlock a substantial government-funded revenue stream, aligning with analyst expectations of the weight-loss drug market exceeding $150 billion in the next decade. The market's positive reception was evidenced by Eli Lilly's shares rising nearly 2% in premarket trading following the news. However, significant hurdles remain. The high annual cost of these drugs, cited at $5,000 to $7,000, poses a considerable fiscal challenge and is a source of potential political friction, highlighted by the differing views of CMS head Mehmet Oz and health secretary Robert F Kennedy Jr. With implementation timelines set for April 2026 for Medicaid and January 2027 for Medicare, the financial impact is not immediate, creating a long-dated catalyst that is subject to implementation and political risks.

Key Decisions for Investors

• This proposed policy shift is a major long-term catalyst for Eli Lilly (LLY) and Novo Nordisk (NVO), justifying a re-evaluation of long-term revenue models to account for the potential inclusion of Medicare and Medicaid patient populations.
• Investors should closely monitor political and regulatory developments, as the plan's significant cost to the public purse and noted internal administration disagreements present considerable implementation risks that could delay or alter the program before its 2026-2027 start dates.
• Given the multi-year timeline until the program's launch, any new or existing positions in the GLP-1 space should be considered with a long-term horizon, acknowledging that near-term volatility will likely be driven by news flow regarding the program's approval and final structure rather than immediate earnings impact.